PTK2 and mesothelioma: However, a Phase-II clinical trial in which patients with Mesothelioma were treated with the FAK inhibitor Defactinib and tested for Merlin expression was terminated early due to lack of improved efficacy as a maintenance therapy for Merlin-low tumors (ClinicalTrials.gov NCT01870609).